Real-Time Clinical Trials (RTCT) is a concept that reimagines how evidence accumulates, how safety is monitored, and how regulatory decisions get made — by making every moment of a trial count, not just the endpoints.
The randomized controlled trial was conceived in an era of paper records, batch data collection, and regulatory review cycles measured in years. The science has advanced. The infrastructure has not.
These are not features or technical specifications. They are conceptual shifts in how clinical evidence is understood, generated, and acted upon.
A safety signal detected six months after its emergence is not meaningful safety monitoring — it is retrospective documentation. RTCT treats the latency between clinical event and decision as a patient safety issue, not an operational inconvenience.
Static protocols designed before a single patient is enrolled assume certainty that doesn't exist at trial initiation. Real-time data enables adaptive designs — adjusting doses, reallocating patients, and refining endpoints as evidence accumulates, not after it has been exhaustively analyzed.
The traditional model treats regulatory review as sequential to evidence generation. RTCT creates the conditions for continuous regulatory engagement — where oversight, safety review, and evidentiary evaluation happen alongside the trial, not after it ends.
RTCT is not a single technology — it is a redesign of the information architecture of a clinical trial, connecting every data-generating moment to every decision-making stakeholder simultaneously.
EDC, EHR, wearable devices, and ePRO feeds flow in real time, mapped to CDISC standards automatically.
AI models monitor accumulating data for adverse event signals, protocol deviations, and anomalies — continuously, across all sites.
DSMB, sponsors, and investigators receive structured intelligence — not raw data — enabling evidence-based mid-trial decisions.
FDA and global regulators access a continuously updated, audit-ready data stream — replacing the retrospective submission cycle.
Enrolled participants receive real-time transparency into their own contribution — improving retention, trust, and informed consent quality.
For every Medinexo Member, Medinexo sets up a ResearchNexo Investigator Profile (RNX-IP) — a feasibility dataset derived from the site's own real-world patient data. The RNX-IP enables a site to demonstrate to sponsors that it has a genuine, qualified patient cohort available for a specific study — not a projection, not a historical estimate, but evidence of actual patients who exist in the site's practice today. In the context of RTCT, the RNX-IP is where real-time feasibility begins: before a protocol is finalized, before a contract is signed, before a single screen failure is recorded.
Before a protocol is finalized, Medinexo sets up a ResearchNexo Investigator Profile (RNX-IP) for each Medinexo Member site — a feasibility dataset that enables a site to demonstrate it has a real, qualified patient cohort available for a study. This replaces optimistic projections with empirical evidence: an actual count of eligible patients in that site's own real-world data, ready to show sponsors before a single contract is signed.
Inclusion/exclusion criteria are tested against real-world patient populations before protocol lock — identifying restrictions that will unnecessarily narrow enrollment without corresponding scientific benefit.
Medinexo Member sites carry an RNX-IP — a live feasibility profile built from their real patient data. Sponsors evaluating sites see an actual cohort, not a historical track record. Sites with an RNX-IP can demonstrate real patient availability for a specific study from day one of sponsor engagement.
AI monitors EHR data at participating sites continuously, surfacing newly eligible patients as they meet protocol criteria through routine clinical encounters — replacing referral-dependent recruitment with proactive identification.
Accumulating data informs pre-specified adaptive decisions — dose adjustments, arm eliminations, sample size re-estimations — grounded in the actual evidence emerging from the trial, not projections made at initiation.
After approval, real-time monitoring of the real-world patient population — including subgroups underrepresented in the registration trial — provides continuous pharmacovigilance and generates the evidence base for label expansion.
Sponsors today manage trials through periodic snapshots — receiving data in aggregated batches that are already weeks old by the time they arrive. RTCT gives sponsors a living view of every trial — enrollment velocity, safety signals, protocol adherence, and site performance — enabling proactive management rather than reactive crisis response.
RTCT creates the conditions for a new model of regulatory engagement — one where FDA and global agencies maintain ongoing visibility into trial conduct and accumulating evidence throughout the trial, not only at submission. This concurrent oversight model enables faster, more confident regulatory decisions grounded in real-time understanding of trial quality and data integrity.
DSMBs convene to review data that was already old when it was prepared for the meeting. RTCT provides DSMBs with structured, continuously updated analyses — safety summaries, efficacy trends, and statistical stopping boundaries — evaluated against accumulating evidence, not against a frozen snapshot prepared weeks before the scheduled review.
Trial participants currently contribute their data into a process that is entirely opaque to them. RTCT makes participant transparency a design principle — giving enrolled patients real-time access to their own data, their contribution to the trial's progress, and the emerging evidence their participation is generating. This transparency drives retention, trust, and more meaningful informed consent.
FDA and global regulators have been signaling for years that clinical trial modernization — including real-time data access, adaptive designs, and continuous safety monitoring — is not aspirational. It is expected.
RTCT aligns with — and in many cases directly enables compliance with — current and emerging FDA guidance on decentralized trials, real-world evidence, diversity action plans, and adaptive design. Every architectural principle of RTCT was developed with regulatory defensibility as a first-order requirement.
FDA's 2023 DCT guidance and evolving real-world evidence framework directly anticipate the continuous data flows and remote monitoring approaches that define RTCT — making regulatory-aligned RTCT implementation achievable today, not aspirational.
ICH E8(R1) requires that trial design decisions — including monitoring approaches and endpoint selection — be grounded in the actual risk profile of the study. Real-time data is the most direct expression of that principle. E6(R3) explicitly supports risk-based monitoring approaches that RTCT enables structurally.
EMA's DARWIN EU framework for real-world evidence is architecturally compatible with RTCT's federated data approach. GDPR data minimization and purpose limitation requirements are satisfied by designs in which patient-level data never leaves its institutional boundary.
Medinexo works with sponsors and investigators to apply RTCT principles to specific indications, protocols, and regulatory strategies. Let's talk about what's possible for your program.